SUN Mingyao 1,2 , TIAN Chen 1,3 , LI Ying 1,3 , SHI Jiaheng 4 , TIAN Jinhui 5,6,7 , LIU Yu 8,9 , LIU Yafei 1,3 , LIU Yajie 8,9 , ZHU Hongfei 1,3 , WU Zhixiong 10 , YANG Jinliang 4 , YANG Kehu 5,6,7 , CHEN Yaolong 5,6,7 , ZHOU Min 11 , ZHOU Qi 5,6,7 , BAI Tao 12 , ZHAO Chen 8 , SHANG Hongcai 13 , LI Mengting 1,3 , DONG Guoju 14 , GE Long 1,3,5,6
  • 1. Evidence-Based Social Science Research Center, School of Public Health, Lanzhou University, Lanzhou 730000, P. R. China;
  • 2. Evidence-Based Nursing Center, School of Nursing, Lanzhou University, Lanzhou 730000, P. R. China;
  • 3. Department of Social Science and Health Management, School of Public Health, Lanzhou University, Lanzhou 730000, P. R. China;
  • 4. Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing 100700, P. R. China;
  • 5. Key Laboratory of Evidence Based Medicine and Knowledge Translation of Gansu Province, Lanzhou 730000, P. R. China;
  • 6. WHO Collaborating Center for Guideline Implementation and Knowledge Translation, Lanzhou 730000, P. R. China;
  • 7. Evidence-Based Medicine Center, School of Basic Medical Sciences, Lanzhou University, Lanzhou 730000, P. R. China;
  • 8. Institute of Basic Research in Clinical, China Academy of Chinese Medical Sciences, Beijing 100700, P. R. China;
  • 9. China Center for Evidence-Based Traditional Chinese Medicine, Beijing 100700, P. R. China;
  • 10. Department of Critical Care Medicine, Huadong Hospital, Fudan University, Shanghai 200040, P. R. China;
  • 11. Department of Respiratory and Critical Care Medicine Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, P. R. China;
  • 12. Department of Infectious Diseases, Wuhan Jinyintan Hospital, Wuhan, 430000, P. R. China;
  • 13. Key Laboratory of Chinese Internal Medicine of Ministry of Education, Dongzhimen Hospital, Beijing University of Traditional Chinese Medicine, Beijing 100700, P. R. China;
  • 14. Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100700, P. R. China;
GE Long, Email: gelong2009@163.com
COVID-19; SARS-CoV-2; Evidence-based practice points
10.7507/1672-2531.202301030
Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables References Cited by

Objective In order to summarize the best evidence, evaluate the efficacy and safety of interventions for the treatment of COVID-19, and provide practical guidance for medical workers, public health workers, and COVID-19 patients, we formulated the evidence-based practice points. Methods We followed the "Evidence-based practice points: methods and processes of development", with comprehensively considering the pros and cons of evidence, quality of evidence, public and patient preferences and values, cost of interventions, acceptability, and feasibility based on systematic reviews. Practice points  Finally, 12 practice points were formed for non-severe, severe and critical COVID-19 patients. Non-severe: ① Consider Hanshiyi formula or Gegenqinlian pills for patients with nausea, vomiting and diarrhea; ② Consider Huashibaidu granules (decoration), Jinyinhua oral liquid, Jinhuaqinggan granules, Xuanfeibaidu granules (decoration), Lianhuaqingwen capsules (granules), or Reyanning mixture for patients with sore throat, fever, muscle aches or cough; ③ Consider Qingfeipaidu granules (decoration) for patients with nasal congestion, runny nose, cough, low-grade fever, aversion to wind and cold, and fatigue; ④ Consider Toujiequwen granules for patients with fever, chills, itchy throat, cough, dry mouth and throat, and constipation; ⑤ Consider Reduning injection or Xiyanping injection for patients with high fever, mild aversion to wind and cold, headache and body pain, cough, and yellow phlegm; ⑥ Consider molnupiravir, nirmatrelvir–ritonavir (Paxlovid), remdesivir or VV116 for patients within 5 to 7 days of the onset of symptoms and at high risk for progressing to severe disease. Severe: ① Consider Shenhuang granules or Xuebijing injection for patients with high fever, irritability, and thirst; ② Consider remdesivir used as soon as possible for patients with severe symptoms. Critical severe: Consider corticosteroids, IL-6 receptor inhibitors, and baricitinib for patients 7 days after the onset of symptoms.

Citation： SUN Mingyao, TIAN Chen, LI Ying, SHI Jiaheng, TIAN Jinhui, LIU Yu, LIU Yafei, LIU Yajie, ZHU Hongfei, WU Zhixiong, YANG Jinliang, YANG Kehu, CHEN Yaolong, ZHOU Min, ZHOU Qi, BAI Tao, ZHAO Chen, SHANG Hongcai, LI Mengting, DONG Guoju, GE Long. Evidence-based practice points: drugs for confirmed COVID-19. Chinese Journal of Evidence-Based Medicine, 2023, 23(7): 745-754. doi: 10.7507/1672-2531.202301030 Copy

  • Next Article

    Therapeutic regimen interpretation of American AAO-HNSF guidelines for sudden hearing loss (2019 update)